Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales

Eli Lilly Q3 Earnings Beat Estimates, Boosts FY21 Guidance On Higher COVID-19 Therapy Sales
  • Eli Lilly And Co LLY has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y.
  • Higher sales were driven by a 17% increase in volume and a 1% increase due to the favorable impact of foreign exchange rates. Net realized prices were essentially flat.
  • Key growth products included Trulicity, Taltz, Verzenio, Jardiance, Emgality, Olumiant, Tyvyt, Retevmo, and Cyramza.
  • Revenue from COVID-19 therapies during the quarter reached $423.5 million.
  • The gross margin was 78.9%, an increase of 2.0 percentage points. Adjusted operating margin reached 30.5%.
  • Adjusted EPS increased 38% Y/Y to $1.94, sharply ahead of the consensus of $1.68.
  • FY21 guidance: Eli Lilly anticipates revenue of $27.2 billion - $27.6 billion, better than $26.8 billion - $27.4 billion previously expected, reflecting additional revenue from COVID-19 antibodies and the core business.
  • It forecasts revenue from COVID-19 therapies of $1.3 billion, higher than $1.0 billion - $1.1 billion, anticipated earlier.
  • Lilly sees adjusted EPS $7.95 - $8.05, better than the prior guidance of $7.80 - $8.00, versus the consensus of $6.80.
  • Related: AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody.
  • Price Action: LLY shares are up 0.18% at $245.5 during the premarket session on the last check Tuesday.

Posted In: BriefsBiotechEarningsNewsGuidanceHealth CareGeneral